Sionna Therapeutics, Inc.
- SION · Nasdaq
- Pharmaceutical Preparations
- Waltham, MA
- 59 employees
- CIK 0002036042
Updated from SEC filings through
Top things to know
Executives
- Michael Cloonan President & CEO Form 4, September 18, 2026
- Elena Ridloff CFO and CBO Form 4, September 18, 2026
- Caroline Stark Beer Chief Business Officer Form 4, January 6, 2026
- Charlotte McKee CMO and Head of R&D Form 4, September 18, 2026
- Jennifer Fitzpatrick CLO and Head of Program Mgmt. Form 4, September 18, 2026
What leadership is saying
“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination”
Earnings press release (8-K Ex. 99.1), filed November 10, 2026
Sionna Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Waltham, MA. It trades as SION on Nasdaq. It reported about 59 employees. Michael Cloonan is President & CEO.
Five-year financials
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | Not on file | Not on file |
| Operating income | -$89.0M 10-K, 2026-03-02 | -$70.6M 10-K, 2026-03-02 |
| SG&A | $28.7M 10-K, 2026-03-02 | $13.3M 10-K, 2026-03-02 |
| Net income | -$75.3M 10-K, 2026-03-02 | -$61.7M 10-K, 2026-03-02 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Michael Cloonan President and Chief Executive Officer, Sionna Therapeutics | President & CEO | Form 4, September 18, 2026 |
| Elena Ridloff | CFO and CBO | Form 4, September 18, 2026 |
| Caroline Stark Beer | Chief Business Officer | Form 4, January 6, 2026 |
| Charlotte McKee | CMO and Head of R&D | Form 4, September 18, 2026 |
| Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | Form 4, September 18, 2026 |
What Sionna Therapeutics, Inc. does
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 45.2 million (as of October 30, 2026) | 10-Q, November 10, 2026 |
|---|---|---|
| Public float | $342M (as of June 30, 2025) | 10-K, March 2, 2026 |
| Reportable segments | 1 (period ending December 31, 2025) | 10-K, March 2, 2026 |
| Latest proxy statement | Meeting June 17, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | Deloitte & Touche LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 17, 2026 | Rajeev M. Shah Director | Sale | 3,448,811 | $21.8M | Form 4, September 21, 2026 |
| September 17, 2026 | Capital Nexus Fund L.P. RA Director | Sale | 3,448,811 | $21.8M | Form 4, September 21, 2026 |
| September 17, 2026 | Capital Nexus Fund L.P. RA III Director | Sale | 3,448,811 | $21.8M | Form 4, September 21, 2026 |
| September 17, 2026 | Capital Healthcare Fund LP RA Director | Sale | 3,448,811 | $21.8M | Form 4, September 21, 2026 |
| September 17, 2026 | Capital Management L.P. Ra Director | Sale | 3,448,811 | $21.8M | Form 4, September 21, 2026 |
| September 17, 2026 | Peter Kolchinsky Director | Sale | 3,448,811 | $21.8M | Form 4, September 21, 2026 |
| July 7, 2026 | Peter A. Thompson Director | Sale | 85,918 | $3.9M | Form 4, July 9, 2026 |
| July 7, 2026 | Advisors Llc Orbimed Director | Sale | 85,918 | $3.9M | Form 4, July 9, 2026 |
Recent 8-K events
- 8-K filed 2026-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-14
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
- 8-K filed 2026-08-10
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-18
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-08-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-06-13
- Item 5.07 Submission of matters to a vote of security holders
Frequently asked questions about Sionna Therapeutics, Inc.
- What does Sionna Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function."
- How many employees does Sionna Therapeutics, Inc. have?
- About 59 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Sionna Therapeutics, Inc.?
- Michael Cloonan, President & CEO, as named in a 4 filed September 18, 2026.
- Who is the CFO of Sionna Therapeutics, Inc.?
- Elena Ridloff, CFO and CBO, as named in a 4 filed September 18, 2026.
- Where is Sionna Therapeutics, Inc. headquartered?
- Waltham, MA.
- What is Sionna Therapeutics, Inc.'s stock ticker?
- SION on Nasdaq.
- What industry is Sionna Therapeutics, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Sionna Therapeutics, Inc.'s website?
- sionnatx.com. Investor relations: https://investors.sionnatx.com/.
- When does Sionna Therapeutics, Inc. report earnings next?
- February 4, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Sionna Therapeutics, Inc. a public company?
- Yes. Sionna Therapeutics, Inc. files with the SEC under CIK 0002036042 and trades as SION.
- Who audits Sionna Therapeutics, Inc.?
- Deloitte & Touche LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Sionna Therapeutics, Inc. are outstanding?
- 45.2 million shares as of October 30, 2026, from its 10-Q filed November 10, 2026.
- What is Sionna Therapeutics, Inc.'s public float?
- $342M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
- How many business segments does Sionna Therapeutics, Inc. report?
- 1 reportable segment for the period ending December 31, 2025, from its 10-K filed March 2, 2026.
- When is Sionna Therapeutics, Inc.'s annual shareholder meeting?
- June 17, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have Sionna Therapeutics, Inc. insiders traded stock recently?
- Since November 21, 2025, officers and directors reported 45 open-market sales worth about $305M and 0 purchases on Forms 4 and 5. The most recent: Rajeev M. Shah (Director) sold 3,448,811 shares on September 17, 2026.